Regulatory Agenda, 9578-9587 [2024-00453]
Download as PDF
9578
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
FOR FURTHER INFORMATION CONTACT:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Elizabeth J. Gramling, Executive
Secretary, Department of Health and
Office of the Secretary
Human Services, 200 Independence
Avenue SW, Washington, DC 20201;
21 CFR Ch. I
(202) 690–5627.
SUPPLEMENTARY INFORMATION: The
25 CFR Ch. V
Department of Health and Human
Services (HHS) is the Federal
42 CFR Chs. I–V
government’s lead agency for protecting
the health of all Americans and
45 CFR Subtitle A; Subtitle B, Chs. II,
providing essential human services.
III, and XIII
HHS enhances the health and wellbeing of Americans by promoting
Regulatory Agenda
effective health and human services and
by fostering sound, sustained advances
AGENCY: Office of the Secretary, HHS.
ACTION: Semiannual Regulatory Agenda. in the sciences underlying medicine,
public health, and social services.
This Agenda presents the regulatory
SUMMARY: The Regulatory Flexibility Act
activities that the Department expects to
of 1980 and Executive Order (E.O.)
undertake in the foreseeable future to
12866 require the semiannual issuance
advance this mission. The purpose of
of an inventory of rulemaking actions
the Agenda is to encourage more
under development throughout the
effective public participation in the
Department, offering for public review
regulatory process. The regulatory
summarized information about
actions forecasted in this Agenda reflect
forthcoming regulatory actions.
the priorities of HHS Secretary Xavier
Becerra and the Biden-Harris
Administration. Accordingly, this
Agenda contains rulemakings aimed at
ensuring that the nation is wellprepared to manage COVID–19 going
forward, building and expanding access
to affordable, quality health care,
addressing health disparities and
promoting equity, and boosting the
mental health and wellbeing of children
and families, among other policy
priorities.
The rulemaking abstracts included in
this paper issue of the Federal Register
cover, as required by the Regulatory
Flexibility Act of 1980, those
prospective HHS rulemakings likely to
have a significant economic impact on
a substantial number of small entities.
The Department’s complete Regulatory
Agenda is accessible online at https://
www.RegInfo.gov.
Elizabeth J. Gramling,
HHS Executive Secretary.
OFFICE FOR CIVIL RIGHTS—PROPOSED RULE STAGE
Regulation
Identifier No.
Sequence No.
Title
313 ....................
Rulemaking on Discrimination on the Basis of Disability in Health and Human Services Programs or Activities (Reg Plan Seq No. 48).
0945–AA15
References in boldface appear in The Regulatory Plan in part II of this issue of the Federal Register.
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION—FINAL RULE STAGE
Regulation
Identifier No.
Sequence No.
Title
314 ....................
Medications for the Treatment of Opioid Use Disorder ...................................................................................
0930–AA39
CENTERS FOR DISEASE CONTROL AND PREVENTION—FINAL RULE STAGE
Regulation
Identifier No.
Sequence No.
Title
315 ....................
Control of Communicable Diseases; Foreign Quarantine (Reg Plan Seq No. 56) ........................................
0920–AA75
References in boldface appear in The Regulatory Plan in part II of this issue of the Federal Register.
FOOD AND DRUG ADMINISTRATION—PROPOSED RULE STAGE
ddrumheller on DSK120RN23PROD with PROPOSALS8
Sequence No.
316
317
318
319
....................
....................
....................
....................
320 ....................
321
322
323
324
....................
....................
....................
....................
Regulation
Identifier No.
Title
Medication Guide; Patient Medication Information ..........................................................................................
Administrative Detention of Tobacco Products ................................................................................................
Conduct of Analytical and Clinical Pharmacology, Bioavailability, and Bioequivalence Studies ....................
Amendments to the Final Rule Regarding the List of Bulk Substances That Can Be Used to Compound
Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act (Section 610 Review).
Distribution of Compounded Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic
Act (Section 610 Review).
Tobacco Product Standard for Nicotine Level of Certain Tobacco Products (Reg Plan Seq No. 57) ..........
Front-of-Package Nutrition Labeling (Reg Plan Seq No. 58) .........................................................................
Medical Devices; Laboratory Developed Tests (Reg Plan Seq No. 59) ........................................................
Registration of Commercial Importers of Drugs; Good Importing Practice .....................................................
References in boldface appear in The Regulatory Plan in part II of this issue of the Federal Register.
VerDate Sep<11>2014
20:53 Feb 08, 2024
Jkt 262001
PO 00000
Frm 00002
Fmt 4701
Sfmt 4702
E:\FR\FM\09FEP8.SGM
09FEP8
0910–AH68
0910–AI05
0910–AI57
0910–AI70
0910–AI71
0910–AI76
0910–AI80
0910–AI85
0910–AI87
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
9579
FOOD AND DRUG ADMINISTRATION—FINAL RULE STAGE
Regulation
Identifier No.
Sequence No.
Title
325 ....................
Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear,
Conspicuous, Neutral Manner in Advertisements in Television and Radio Format.
Sunlamp Products; Amendment to the Performance Standard ......................................................................
General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products ............
Amendments to the List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act.
Requirements for Tobacco Product Manufacturing Practice ...........................................................................
Nutrient Content Claims, Definition of Term: Healthy (Reg Plan Seq No. 61) ..............................................
Tobacco Product Standard for Characterizing Flavors in Cigars (Reg Plan Seq No. 62) .............................
Tobacco Product Standard for Menthol in Cigarettes (Reg Plan Seq No. 64) ..............................................
326 ....................
327 ....................
328 ....................
329
330
331
332
....................
....................
....................
....................
0910–AG27
0910–AG30
0910–AH14
0910–AH81
0910–AH91
0910–AI13
0910–AI28
0910–AI60
References in boldface appear in The Regulatory Plan in part II of this issue of the Federal Register.
FOOD AND DRUG ADMINISTRATION—LONG-TERM ACTIONS
Sequence No.
333
334
335
336
....................
....................
....................
....................
Regulation
Identifier No.
Title
National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers ..
Nicotine Toxicity Warnings ...............................................................................................................................
Certain Requirements Regarding Prescription Drug Marketing (203 Amendment) ........................................
Postmarketing Safety Reporting Requirements, Pharmacovigilance Plans, and Pharmacovigilance Quality
Systems for Human Drug and Biological Products.
0910–AH11
0910–AH24
0910–AH56
0910–AI61
FOOD AND DRUG ADMINISTRATION—COMPLETED ACTIONS
Regulation
Identifier No.
Sequence No.
Title
337 ....................
Revocation of Uses of Partially Hydrogenated Oils in Foods .........................................................................
0910–AI15
CENTERS FOR MEDICARE & MEDICAID SERVICES—PROPOSED RULE STAGE
Regulation
Identifier No.
Sequence No.
Title
338 ....................
CY 2025 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS–1807) (Section 610 Review).
Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals; the Long-Term Care Hospital
Prospective Payment System; and FY 2025 Rates (CMS–1808) (Section 610 Review).
CY 2025 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center
Payment System Policy Changes and Payment Rates (CMS–1809) (Section 610 Review).
339 ....................
340 ....................
0938–AV33
0938–AV34
0938–AV35
CENTERS FOR MEDICARE & MEDICAID SERVICES—FINAL RULE STAGE
Regulation
Identifier No.
Sequence No.
Title
341 ....................
CY 2024 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS–1784) (Section 610 Review).
CY 2024 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center
Payment System Policy Changes and Payment Rates (CMS–1786) (Section 610 Review).
342 ....................
0938–AV07
0938–AV09
ddrumheller on DSK120RN23PROD with PROPOSALS8
CENTERS FOR MEDICARE & MEDICAID SERVICES—COMPLETED ACTIONS
Regulation
Identifier No.
Sequence No.
Title
343 ....................
FY 2024 Skilled Nursing Facility (SNF) PPS and Consolidated Billing and Updates to the Value-Based
Purchasing and Quality Reporting Programs (CMS–1779) (Completion of a Section 610 Review).
CY 2024 Home Health Prospective Payment System Rate Update and Home Infusion Therapy Services
Payment Update (CMS–1780) (Completion of a Section 610 Review).
FY 2024 Inpatient Psychiatric Facilities Prospective Payment System Rate and Quality Reporting Updates
(CMS–1783) (Completion of a Section 610 Review).
Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals; the Long-Term Care Hospital
Prospective Payment System; and FY 2024 Rates (CMS–1785) (Completion of a Section 610 Review).
344 ....................
345 ....................
346 ....................
VerDate Sep<11>2014
20:53 Feb 08, 2024
Jkt 262001
PO 00000
Frm 00003
Fmt 4701
Sfmt 4702
E:\FR\FM\09FEP8.SGM
09FEP8
0938–AV02
0938–AV03
0938–AV06
0938–AV08
9580
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
CENTERS FOR MEDICARE & MEDICAID SERVICES—COMPLETED ACTIONS—Continued
Regulation
Identifier No.
Sequence No.
Title
347 ....................
FY 2024 Hospice Wage Index, Payment Rate Update, and Quality Reporting Requirements (CMS–1787)
(Completion of a Section 610 Review).
Hospital Outpatient Prospective Payment System: Remedy for 340B-Acquired Drugs Purchased in Cost
Years 2018–2022 (CMS–1793) (Section 610 Review) (Reg Plan Seq No. 77).
348 ....................
0938–AV10
0938–AV18
References in boldface appear in The Regulatory Plan in part II of this issue of the Federal Register.
ADMINISTRATION FOR CHILDREN AND FAMILIES—PROPOSED RULE STAGE
Regulation
Identifier No.
Sequence No.
Title
349 ....................
350 ....................
Supporting the Head Start Workforce and Other Quality Improvements (Reg Plan Seq No. 80) .................
Safe and Appropriate Foster Care Placement Requirements for Titles IV–E and IV–B (Section 610 Review) (Reg Plan Seq No. 81).
0970–AD01
0970–AD03
References in boldface appear in The Regulatory Plan in part II of this issue of the Federal Register.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Office for Civil Rights (OCR)
Proposed Rule Stage
313. Rulemaking on Discrimination on
the Basis of Disability in Health and
Human Services Programs or Activities
[0945–AA15]
Regulatory Plan: This entry is Seq.
No. 48 in part II of this issue of the
Federal Register.
RIN: 0945–AA15
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Action
Final Rule Stage
ddrumheller on DSK120RN23PROD with PROPOSALS8
314. Medications for the Treatment of
Opioid Use Disorder [0930–AA39]
Legal Authority: 21 U.S.C. 823(g)(1)
Abstract: The Substance Abuse and
Mental Health Services Administration
(SAMHSA) will revise 42 CFR part 8 to
make permanent some regulatory
flexibilities for Opioid Treatment
Programs (OTPs) granted under the
COVID–19 Public Health Emergency
(PHE), and to expand access to care for
people with Opioid Use Disorder
(OUD). Specifically, SAMHSA will
update criteria pertaining to
unsupervised doses of methadone and
also initiation of buprenorphine via
telemedicine. To expand access to care,
SAMHSA will also update admission
criteria, particularly those rules that
may limit timely access to treatment in
an OTP. To achieve this, sections of 42
CFR part 8 will require updating.
SAMHSA’s changes will impact roughly
20:53 Feb 08, 2024
Jkt 262001
Date
FR Cite
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Centers for Disease Control and
Prevention (CDC)
Final Rule Stage
315. Control of Communicable Diseases;
Foreign Quarantine [0920–AA75]
Regulatory Plan: This entry is Seq.
No. 56 in part II of this issue of the
Federal Register.
RIN: 0920–AA75
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Food and Drug Administration (FDA)
Substance Abuse and Mental Health
Services Administration (SAMHSA)
VerDate Sep<11>2014
1900 opioid treatment programs and
state opioid treatment authorities.
In response to the Consolidated
Appropriations Act of 2023, which
removed the requirement to obtain a
waiver in order to prescribe certain
schedule III–V medications for the
treatment of OUD, SAMHSA issued a
supplemental notice of proposed
rulemaking on Feb. 13, 2023, (88 FR
9221) calling for additional public
comment on SAMHSA’s plans to
remove reference to the Drug Addiction
Treatment Act of 2000 (DATA 2000Waiver) from 42 CFR part 8.
Timetable:
NPRM ..................
Supplemental
NPRM.
NPRM Comment
Period End.
Supplemental
NPRM Comment Period
End.
Final Action .........
12/16/22
02/13/23
87 FR 77330
88 FR 9221
316. Medication Guide; Patient
Medication Information [0910–AH68]
02/14/23
03/14/23
01/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Dr. Neeraj Gandotra,
Chief Medical Officer, Department of
Health and Human Services, Substance
Abuse and Mental Health Services
Administration, 5600 Fishers Lane,
18E67, Rockville, MD 20857, Phone: 202
823–1816, Email: neeraj.gandotra@
samhsa.hhs.gov.
RIN: 0930–AA39
PO 00000
Frm 00004
Fmt 4701
Sfmt 4702
Proposed Rule Stage
Legal Authority: 21 U.S.C. 321 et seq.;
42 U.S.C. 262; 42 U.S.C. 264; 21 U.S.C.
371
Abstract: The rule will amend FDA
medication guide regulations to require
a new form of patient labeling, namely
Patient Medication Information, for
submission to and review by FDA for
human prescription drug products and
certain blood products used, dispensed,
or administered on an outpatient basis.
The rule will include requirements for
the development and distribution of
Patient Medication Information. The
rule will require clear and concisely
written prescription drug product
information presented in a consistent
and easily understood format to help
patients use their prescription drug
products safely and effectively.
Timetable:
E:\FR\FM\09FEP8.SGM
09FEP8
9581
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
Action
Date
NPRM ..................
NPRM Comment
Period End.
Final Action .........
FR Cite
05/31/23
11/27/23
I
03/00/26
88 FR 35694
318. Conduct of Analytical and Clinical
Pharmacology, Bioavailability, and
Bioequivalence Studies [0910–AI57]
I
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Chris Wheeler,
Supervisory Project Manager,
Department of Health and Human
Services, Food and Drug
Administration, 10903 New Hampshire
Avenue, Building 51, Room 3330, Silver
Spring, MD 20993, Phone: 301 796–
0151, Email: chris.wheeler@fda.hhs.gov.
RIN: 0910–AH68
317. Administrative Detention of
Tobacco Products [0910–AI05]
Legal Authority: 21 U.S.C. 334; 21
U.S.C. 371
Abstract: FDA is proposing a
regulation to establish requirements for
the administrative detention of tobacco
products. This proposed rule, when
finalized, would allow FDA to
administratively detain tobacco
products encountered during
inspections of manufacturers or other
establishments that manufacture,
process, pack, or hold tobacco products
that an authorized FDA representative
conducting the inspection has reason to
believe are adulterated or misbranded.
The intent of administrative detention is
to protect public health by preventing
the distribution or use of tobacco
products encountered during
inspections that are believed to be
adulterated or misbranded until FDA
has had time to consider the appropriate
action to take and, where appropriate, to
initiate legal action.
Timetable:
Action
Date
ddrumheller on DSK120RN23PROD with PROPOSALS8
NPRM ..................
FR Cite
10/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Quynh Nguyen,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, Center for
Tobacco Products, 10903 New
Hampshire Avenue, Document Control
Center, Building 71, Room G335, Silver
Spring, MD 20993, Phone: 877 287–
1373, Email: ctpregulations@
fda.hhs.gov.
Laura Chilaka, Regulatory Counsel,
Department of Health and Human
Services, Food and Drug
Administration, Center for Tobacco
Products, 10903 New Hampshire
Avenue, Document Control Center,
Building 71, Room G335, Silver Spring,
VerDate Sep<11>2014
20:53 Feb 08, 2024
MD 20993, Phone: 877 287–1373, Email:
ctpregulations@fda.hhs.gov.
RIN: 0910–AI05
Jkt 262001
Legal Authority: 21 U.S.C. 355; 21
U.S.C. 371; 21 U.S.C. 374; 42 U.S.C. 262
Abstract: FDA is proposing to amend
21 CFR 320, in certain parts, and
establish a new 21 CFR 321 to clarify
FDA’s study conduct expectations for
clinical pharmacology, and clinical and
analytical bioavailability (BA) and
bioequivalence (BE) studies that support
marketing applications for human drug
and biological products. The proposed
rule would specify needed basic study
conduct requirements to enable FDA to
ensure those studies are conducted
appropriately and to verify the
reliability of study data from those
studies. This regulation would align
with FDA’s other good practice
regulations, would also be consistent
with current industry best practices, and
would harmonize the regulations more
closely with related international
regulatory expectations.
Timetable:
Action
Date
NPRM ..................
FR Cite
04/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Brian Joseph Folian,
Supervisory Biologist, Department of
Health and Human Services, Food and
Drug Administration, 10903 New
Hampshire Avenue, Building 51, Room
5215, Silver Spring, MD 20993–0002,
Phone: 240 402–4089, Email:
brian.folian@fda.hhs.gov.
RIN: 0910–AI57
319. Amendments to the Final Rule
Regarding the List of Bulk Substances
That Can Be Used To Compound Drug
Products in Accordance With Section
503A of the Federal Food, Drug, and
Cosmetic Act (Section 610 Review)
[0910–AI70]
Legal Authority: 21 U.S.C. 353a; 21
U.S.C. 351; 21 U.S.C. 371(a); 21 U.S.C.
352; 21 U.S.C. 355
Abstract: FDA has issued a regulation
creating a list of bulk drug substances
(active pharmaceutical ingredients) that
can be used to compound drug products
in accordance with section 503A of the
Federal Food, Drug, and Cosmetic Act,
although they are neither the subject of
an applicable United States
Pharmacopeia (USP) or National
Formulary (NF) monograph nor
components of FDA-approved drug
PO 00000
Frm 00005
Fmt 4701
Sfmt 4702
products (the 503A Bulks List). The
proposed rule will identify certain bulk
drug substances that FDA has
considered and is proposing to place on
the 503A Bulks List and certain bulk
drug substances that FDA has
considered and is proposing not to
include on the 503A Bulks List.
Timetable:
Action
NPRM ..................
Date
FR Cite
10/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Rosilend Lawson,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, 10903 New
Hampshire Avenue, Building 51, Room
5197, Silver Spring, MD 20993, Phone:
240 402–6223, Email: rosilend.lawson@
fda.hhs.gov.
RIN: 0910–AI70
320. Distribution of Compounded Drug
Products Under Section 503A of the
Federal Food, Drug, and Cosmetic Act
(Section 610 Review) [0910–AI71]
Legal Authority: 21 U.S.C. 351; 21
U.S.C. 352; 21 U.S.C. 353a; 21 U.S.C.
353a–1; 21 U.S.C. 355; 21 U.S.C. 371
Abstract: The Food and Drug
Administration is proposing rulemaking
regarding statutory requirements under
section 503A of the Federal Food, Drug,
and Cosmetic Act for certain
distributions of compounded human
drug products. The proposed rule, if
finalized, will include provisions
regarding a standard memorandum of
understanding (MOU) that describes the
responsibilities of a State Board of
Pharmacy or other appropriate State
agency that chooses to sign the standard
MOU in investigating complaints
related to drug products compounded in
such State and distributed outside such
State and in addressing the interstate
distribution of inordinate amounts of
compounded human drug products. It
will also, if finalized, include provisions
regarding the statutory 5 percent limit
on distribution of compounded human
drug products out of the State in which
they are compounded in States that do
not sign the standard MOU. The rule,
will also, if finalized, address
communication with State boards of
pharmacy.
Timetable:
Action
NPRM ..................
Date
FR Cite
12/00/23
Regulatory Flexibility Analysis
Required: Yes.
E:\FR\FM\09FEP8.SGM
09FEP8
9582
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
Agency Contact: Dominic Markwordt,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, Center for Drug
Evaluation and Research, 10903 New
Hampshire Avenue, Building 51, Room
5104, Silver Spring, MD 20993, Phone:
301 796–9349, Email:
dominic.markwordt@fda.hhs.gov.
RIN: 0910–AI71
321. Tobacco Product Standard for
Nicotine Level of Certain Tobacco
Products [0910–AI76]
Regulatory Plan: This entry is Seq.
No. 57 in part II of this issue of the
Federal Register.
RIN: 0910–AI76
Action
Date
FR Cite
322. Front-of-Package Nutrition
Labeling [0910–AI80]
NPRM ..................
Regulatory Plan: This entry is Seq.
No. 58 in part II of this issue of the
Federal Register.
RIN: 0910–AI80
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: James Hanratty,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, WO 75, Rm.
1607A, 10903 New Hampshire Avenue,
Silver Spring, MD 20993, Phone: 240
402–4718, Email: james.hanratty@
fda.hhs.gov.
RIN: 0910–AI87
323. Medical Devices; Laboratory
Developed Tests [0910–AI85]
Regulatory Plan: This entry is Seq.
No. 59 in part II of this issue of the
Federal Register.
RIN: 0910–AI85
324. Registration of Commercial
Importers of Drugs; Good Importing
Practice [0910–AI87]
ddrumheller on DSK120RN23PROD with PROPOSALS8
due diligence required by the importer
regarding the safety of the drugs. There
would also be cost savings to both FDA
and industry from facilitating the review
of documentation that ensures
compliance with our regulations prior to
being allowed to enter the United States.
This proposed rulemaking will also
enhance FDA’s ability to collect and
analyze data to enable risk-informed
decision-making while focusing on
protecting the integrity of the global
drug supply chain and ensuring safety,
effectiveness, and quality of imported
drugs.
Timetable:
Legal Authority: sec. 714 of the Food
and Drug Administrative Safety and
Innovation Act (FDASIA) of July 2012
Abstract: This proposed rulemaking
meets the mandate of section 714 of the
Food and Drug Administration Safety
and Innovation Act and will establish
registration and good importing practice
requirements for commercial importers
of drugs. Although manufacturers are
subject to regulatory requirements to
ensure such quality standards are met,
there are few clear responsibilities for
commercial importers of drugs to do the
same.
Cost estimates of the rule include
reading and understanding the rule,
registering as a commercial importer
through the Food and Drug
Administration’s (FDA) electronic
importer registration system, annual
updating of registration, establishing a
quality management system, conducting
risk evaluations of drugs and suppliers,
shipment verifications, investigations,
corrective actions, and records
maintenance.
The unquantified benefits of the
proposed rule include improvement in
the safety of finished drugs allowed to
enter the United States from the
commercial drug importer’s requirement
to register with FDA and for increased
VerDate Sep<11>2014
20:53 Feb 08, 2024
Jkt 262001
01/00/24
This rule also establishes standards for
determining whether the major
statement in these advertisements is
presented in the manner required.
Timetable:
Action
Date
NPRM ..................
NPRM Comment
Period End.
NPRM Comment
Period Reopened.
NPRM Comment
Period End.
NPRM Comment
Period Reopened.
NPRM Comment
Period Reopened End.
Final Rule ............
FR Cite
03/29/10
06/28/10
75 FR 15376
01/27/12
77 FR 4273
02/27/12
03/29/12
77 FR 16973
04/09/12
11/00/23
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Suzanna Boyle,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, 10903 New
Hampshire Avenue, WO 51, Room 3214,
Silver Spring, MD 20993, Phone: 240
402–4723, Email: suzanna.boyle@
fda.hhs.gov.
RIN: 0910–AG27
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
326. Sunlamp Products; Amendment to
the Performance Standard [0910–AG30]
Food and Drug Administration (FDA)
Legal Authority: 21 U.S.C. 360ii; 21
U.S.C. 360kk; 21 U.S.C. 393; 21 U.S.C.
371
Abstract: FDA is updating the
performance standard for sunlamp
products and ultraviolet lamps intended
for use in these products to improve
safety, reflect new scientific
information, and work towards
harmonization with international
standards. By harmonizing with the
International Electrotechnical
Commission, this rule will decrease the
regulatory burden on industry and allow
the Agency to take advantage of the
expertise of the international
committees, thereby also saving
resources.
Timetable:
Final Rule Stage
325. Direct-to-Consumer Prescription
Drug Advertisements: Presentation of
the Major Statement in a Clear,
Conspicuous, Neutral Manner in
Advertisements in Television and
Radio Format [0910–AG27]
Legal Authority: 21 U.S.C. 321; 21
U.S.C. 331; 21 U.S.C. 352; 21 U.S.C. 355;
21 U.S.C. 360b; 21 U.S.C. 371; . . .
Abstract: The Food and Drug
Administration (FDA) is amending its
regulations concerning direct-toconsumer (DTC) advertisements of
prescription drugs. Prescription drug
advertisements presented through
media such as TV and radio must
disclose the product’s major side effects
and contraindications in what is
sometimes called the major statement.
The rule would revise the regulation to
reflect the statutory requirement that in
DTC advertisements for human
prescription drugs presented in
television or radio format and stating
the name of the drug and its conditions
of use, the major statement relating to
side effects and contraindications of the
advertised drug must be presented in a
clear, conspicuous, and neutral manner.
PO 00000
Frm 00006
Fmt 4701
Sfmt 4702
Action
NPRM ..................
NPRM Comment
Period End.
Final Rule ............
Date
12/22/15
03/21/16
I
FR Cite
80 FR 79505
03/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Ian Ostermiller,
Regulatory Counsel, Center for Devices
and Radiological Health, Department of
Health and Human Services, Food and
E:\FR\FM\09FEP8.SGM
09FEP8
9583
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
Drug Administration, 10903 New
Hampshire Avenue, WO 66, Room 5454,
Silver Spring, MD 20993, Phone: 301
796–5678, Email: ian.ostermiller@
fda.hhs.gov.
RIN: 0910–AG30
327. General and Plastic Surgery
Devices: Restricted Sale, Distribution,
and Use of Sunlamp Products [0910–
AH14]
Legal Authority: 21 U.S.C. 360j(e)
Abstract: This rule will apply device
restrictions to sunlamp products.
Sunlamp products include ultraviolet
(UV) lamps and UV tanning beds and
booths. The incidence of skin cancer,
including melanoma, has been
increasing, and a large number of skin
cancer cases are attributable to the use
of sunlamp products. The devices may
cause about 400,000 cases of skin cancer
per year, and 6,000 of which are
melanoma. Beginning use of sunlamp
products at young ages, as well as
frequently using sunlamp products,
both increases the risk of developing
skin cancers and other illnesses, and
sustaining other injuries. Even
infrequent use, particularly at younger
ages, can significantly increase these
risks.
Timetable:
Action
Date
NPRM ..................
NPRM Comment
Period End.
Final Rule ............
FR Cite
12/22/15
03/21/16
I
03/00/24
80 FR 79493
I
ddrumheller on DSK120RN23PROD with PROPOSALS8
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Daniel Schieffer,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, Center for Devices
and Radiological Health, 10903 New
Hampshire Avenue, WO 75, Room 7613,
Silver Spring, MD 20993, Phone: 301
796–3350, Email: daniel.schieffer@
fda.hhs.gov.
RIN: 0910–AH14
328. Amendments to the List of Bulk
Drug Substances That Can Be Used To
Compound Drug Products in
Accordance With Section 503A of the
Federal Food, Drug, and Cosmetic Act
[0910–AH81]
Legal Authority: 21 U.S.C. 351; 21
U.S.C. 352; 21 U.S.C. 353a; 21 U.S.C.
355; 21 U.S.C. 371
Abstract: FDA has issued a regulation
creating a list of bulk drug substances
(active pharmaceutical ingredients) that
can be used to compound drug products
in accordance with section 503A of the
Federal Food, Drug, and Cosmetic Act
(FD&C Act), although they are neither
VerDate Sep<11>2014
20:53 Feb 08, 2024
Jkt 262001
the subject of an applicable United
States Pharmacopeia (USP) or National
Formulary (NF) monograph nor
components of FDA-approved drugs
(the 503A Bulks List). FDA has
proposed to amend the 503A Bulks List
by placing additional bulk drug
substances on the list. FDA has also
identified bulk drug substances that
FDA has considered and proposed not
to include on the 503A Bulks List.
Additional substances nominated by the
public for inclusion on this list are
currently under consideration and will
be the subject of future rulemaking.
Timetable:
Action
Date
NPRM ..................
NPRM Comment
Period End.
Final Rule ............
FR Cite
09/05/19
12/04/19
I
10/00/24
84 FR 46688
I
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Rosilend Lawson,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, 10903 New
Hampshire Avenue, Building 51, Room
5197, Silver Spring, MD 20993, Phone:
240 402–6223, Email: rosilend.lawson@
fda.hhs.gov.
RIN: 0910–AH81
329. Requirements for Tobacco Product
Manufacturing Practice [0910–AH91]
Legal Authority: 21 U.S.C. 371; 21
U.S.C. 374; 21 U.S.C. 381(a); 21 U.S.C.
387b; 21 U.S.C. 387c; 21 U.S.C. 387f; 21
U.S.C. 387i; . . .
Abstract: The rule would establish
tobacco product manufacturing practice
(TPMP) requirements for manufacturers
of finished and bulk tobacco products.
This rule, if finalized, would set forth
requirements for the manufacture, preproduction design validation, packing,
and storage of a tobacco product. This
rule would help prevent the
manufacture and distribution of
contaminated and otherwise
nonconforming tobacco products. This
rule provides manufacturers with
flexibility in the manner in which they
comply with the requirements while
giving FDA the ability to enforce
regulatory requirements, thus helping to
assure the protection of public health.
Timetable:
Action
Date
NPRM ..................
NPRM Comment
Period End.
NPRM Comment
Period Extension to Oct. 06,
2023.
PO 00000
Frm 00007
FR Cite
03/10/23
09/06/23
88 FR 15174
08/29/23
88 FR 59481
Fmt 4701
Sfmt 4702
Action
Final Action .........
Date
FR Cite
10/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Matthew Brenner,
Senior Regulatory Counsel, Department
of Health and Human Services, Food
and Drug Administration, Center for
Tobacco Products, 10903 New
Hampshire Avenue, Document Control
Center, Building 71, Room G335, Silver
Spring, MD 20993, Phone: 877 287–
1373, Email: ctpregulations@
fda.hhs.gov.
RIN: 0910–AH91
330. Nutrient Content Claims,
Definition of Term: Healthy [0910–
AI13]
Regulatory Plan: This entry is Seq.
No. 61 in part II of this issue of the
Federal Register.
RIN: 0910–AI13
331. Tobacco Product Standard for
Characterizing Flavors in Cigars [0910–
AI28]
Regulatory Plan: This entry is Seq.
No. 62 in part II of this issue of the
Federal Register.
RIN: 0910–AI28
332. Tobacco Product Standard for
Menthol in Cigarettes [0910–AI60]
Regulatory Plan: This entry is Seq.
No. 64 in part II of this issue of the
Federal Register.
RIN: 0910–AI60
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Food and Drug Administration (FDA)
Long-Term Actions
333. National Standards for the
Licensure of Wholesale Drug
Distributors and Third-Party Logistics
Providers [0910–AH11]
Legal Authority: secs. 583 and 584 of
the FD&C Act, as added by the DSCSA
under Pub. L. 113–54, together with
related FD&C Act authority added by
the DSCSA
Abstract: The final rule establishes
national standards for State licensing of
prescription drug wholesale distributors
and third-party logistics providers. The
rulemaking also establishes a Federal
system for wholesale drug distributor
and third-party logistics provider
licensing for use in the absence of a
State licensure program.
E:\FR\FM\09FEP8.SGM
09FEP8
9584
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
Timetable:
Action
Date
NPRM ..................
NPRM Comment
Period End.
NPRM Comment
Period Extended.
NPRM Comment
Period Extended End.
Final Rule ............
FR Cite
02/04/22
06/06/22
87 FR 6708
05/24/22
87 FR 31439
09/06/22
04/00/25
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Aaron Weisbuch,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, Center for Drug
Evaluation and Research, Building 51,
Room 4261, 10903 New Hampshire
Avenue, Silver Spring, MD 20993,
Phone: 301 796–9362, Email:
aaron.weisbuch@fda.hhs.gov.
RIN: 0910–AH11
334. Nicotine Toxicity Warnings [0910–
AH24]
Legal Authority: 21 U.S.C. 301 et seq.;
21 U.S.C. 331; 21 U.S.C. 371; 21 U.S.C.
387f; . . .
Abstract: This rule would establish
acute nicotine toxicity warning
requirements for liquid nicotine and
nicotine-containing e-liquid(s) intended
for human consumption, and potentially
for other tobacco products including,
but not limited to, novel tobacco
products such as dissolvables, lotions,
gels, and drinks. This action is intended
to increase consumer awareness and
knowledge of the risks of acute toxicity
due to accidental nicotine exposure
from nicotine-containing e-liquids in
tobacco products.
Timetable:
Action
Date
ddrumheller on DSK120RN23PROD with PROPOSALS8
NPRM ..................
FR Cite
04/00/25
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Laura Chilaka,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, Center for
Tobacco Products, 10903 New
Hampshire Avenue, Document Control
Center, Building 71, Room G355, Silver
Spring, MD 20993, Phone: 877 287–
1373, Email: ctpregulations@
fda.hhs.gov.
RIN: 0910–AH24
VerDate Sep<11>2014
20:53 Feb 08, 2024
Jkt 262001
335. Certain Requirements Regarding
Prescription Drug Marketing (203
Amendment) [0910–AH56]
Legal Authority: Section 503 and
related provisions of the FD&C Act, as
amended by Pub. L. 113–54
Abstract: The final rule amends Food
and Drug Administration (FDA)
regulations at 21 CFR 203 to remove
provisions no longer in effect and
incorporate conforming changes
following enactment of the Drug Supply
Chain Security Act (DSCSA). The final
rule amends the regulations to clarify
provisions and avoid causing confusion
with the new standards for wholesale
distribution established by DSCSA.
Timetable:
Action
Date
NPRM ..................
NPRM Comment
Period End.
Final Rule ............
FR Cite
02/04/22
04/05/22
I
04/00/25
87 FR 6443
I
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Aaron Weisbuch,
Regulatory Counsel, Department of
Health and Human Services, Food and
Drug Administration, Center for Drug
Evaluation and Research, Building 51,
Room 4261, 10903 New Hampshire
Avenue, Silver Spring, MD 20993,
Phone: 301 796–9362, Email:
aaron.weisbuch@fda.hhs.gov.
RIN: 0910–AH56
336. Postmarketing Safety Reporting
Requirements, Pharmacovigilance
Plans, and Pharmacovigilance Quality
Systems for Human Drug and Biological
Products [0910–AI61]
Legal Authority: 42 U.S.C. 262; 42
U.S.C. 264; 42 U.S.C. 300aa–25; 21
U.S.C. 321; 21 U.S.C. 351 to 353; 21
U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371;
21 U.S.C. 374; . . .
Abstract: The proposed rule would
modernize FDA’s regulations on
postmarketing safety reporting and
pharmacovigilance for human drug and
biological products, including blood
and blood components, by capturing
important new safety-related
information, improving the quality and
utility of submitted reports, and
supporting enhanced alignment with
internationally harmonized reporting
guidelines. Among other things, the
proposed rule would require the
submission of certain nonclinical and
clinical data to FDA in a periodic safety
report, rather than the annual report.
The proposed rule also would require
application holders for drug products
and certain biological products to
establish and maintain a
PO 00000
Frm 00008
Fmt 4701
Sfmt 4702
pharmacovigilance quality system that
reflects the application holder’s unique
needs and that may support a more
streamlined, flexible approach to
satisfying certain postmarketing safety
reporting requirements.
Timetable:
Action
NPRM ..................
Date
FR Cite
10/00/25
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Janice L. Weiner,
Principal Regulatory Counsel,
Department of Health and Human
Services, Food and Drug
Administration, Center for Drug
Evaluation and Research, 10903 New
Hampshire Avenue, Building 51, Room
6270, Silver Spring, MD 20993–0002,
Phone: 301 796–3475, Fax: 301 847–
8440, Email: janice.weiner@fda.hhs.gov.
RIN: 0910–AI61
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Food and Drug Administration (FDA)
Completed Actions
337. Revocation of Uses of Partially
Hydrogenated Oils in Foods [0910–
AI15]
Legal Authority: 21 U.S.C. 321; 21
U.S.C. 341; 21 U.S.C. 342; 21 U.S.C. 343;
21 U.S.C. 348; 21 U.S.C. 371; 21 U.S.C.
379e
Abstract: In the Federal Register of
June 17, 2015 (80 FR 34650), FDA
published a declaratory order
announcing our final determination that
there is no longer a consensus among
qualified experts that partially
hydrogenated oils (PHOs) are generally
recognized as safe (GRAS) for any use in
human food. In the Federal Register of
May 21, 2018 (83 FR 23382), we denied
a food additive petition requesting that
the food additive regulations be
amended to provide for the safe use of
PHOs in certain food applications. Next,
on August 9, 2023, we issued a direct
final rule and companion proposed rule
that would update our regulations to
remove all mention of PHOs from FDA’s
GRAS regulations and as an optional
ingredient in standards of identity. This
action would also revoke all prior
sanctions for uses of PHOs in food.
Completed:
Reason
NPRM ..................
Direct Final Rule
E:\FR\FM\09FEP8.SGM
09FEP8
Date
08/09/23
08/09/23
FR Cite
88 FR 53827
88 FR 53764
9585
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
Reason
Date
Direct Final Rule
Effective.
FR Cite
12/22/23
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Ellen Anderson,
Phone: 240 402–1309, Email:
ellen.anderson@fda.hhs.gov.
RIN: 0910–AI15
prospective payment systems for
operating and capital-related costs. This
proposed rule would implement
changes arising from our continuing
experience with these systems. In
addition, the rule proposes to establish
new requirements or revise existing
requirements for quality reporting by
specific Medicare providers.
Timetable:
Action
NPRM ..................
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Centers for Medicare & Medicaid
Services (CMS)
Proposed Rule Stage
338. • CY 2025 Revisions To Payment
Policies Under the Physician Fee
Schedule and Other Revisions to
Medicare Part B (CMS–1807) (Section
610 Review) [0938–AV33]
Legal Authority: 42 U.S.C. 1302; 42
U.S.C. 1395hh; Pub. L. 117–169
Abstract: This annual proposed rule
would revise payment polices under the
Medicare physician fee schedule, and
make other policy changes to payment
under Medicare Part B. These changes
would apply to services furnished
beginning January 1, 2025. Additionally,
this rule proposes updates to the
Quality Payment Program. This
proposed rule would also codify the
inflation rebate program for Medicare
Part B and Part D drugs established in
the Inflation Reduction Act.
Timetable:
Action
Date
NPRM ..................
FR Cite
06/00/24
ddrumheller on DSK120RN23PROD with PROPOSALS8
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Gift Tee, Director,
Division of Physician Services,
Department of Health and Human
Services, Centers for Medicare &
Medicaid Services, Center for Medicare,
7500 Security Boulevard, MS: C1–09–
07, Baltimore, MD 21244, Phone: 410
786–9316, Email: gift.tee@cms.hhs.gov.
RIN: 0938–AV33
339. • Hospital Inpatient Prospective
Payment Systems for Acute Care
Hospitals; the Long-Term Care Hospital
Prospective Payment System; and FY
2025 Rates (CMS–1808) (Section 610
Review) [0938–AV34]
Legal Authority: 42 U.S.C. 1302; 42
U.S.C. 1395hh
Abstract: This annual proposed rule
would revise the Medicare hospital
inpatient and long-term care hospital
VerDate Sep<11>2014
20:53 Feb 08, 2024
Jkt 262001
Date
FR Cite
04/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Donald Thompson,
Director, Division of Acute Care,
Department of Health and Human
Services, Centers for Medicare &
Medicaid Services, Center for Medicare,
MS: C4–01–26, 7500 Security
Boulevard, Baltimore, MD 21244,
Phone: 410 786–6504, Email:
donald.thompson@cms.hhs.gov.
RIN: 0938–AV34
340. • CY 2025 Hospital Outpatient PPS
Policy Changes and Payment Rates and
Ambulatory Surgical Center Payment
System Policy Changes and Payment
Rates (CMS–1809) (Section 610 Review)
[0938–AV35]
Legal Authority: 42 U.S.C. 1302; 42
U.S.C. 1395hh
Abstract: This annual proposed rule
would revise the Medicare hospital
outpatient prospective payment system
to implement statutory requirements
and changes arising from our continuing
experience with this system. The
proposed rule describes changes to the
amounts and factors used to determine
payment rates for services. In addition,
the rule proposes changes to the
ambulatory surgical center payment
system list of services and rates. This
proposed rule would also update and
refine the requirements for the Hospital
Outpatient Quality Reporting (OQR)
Program and the ASC Quality Reporting
(ASCQR) Program.
Timetable:
Action
Date
NPRM ..................
FR Cite
06/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Elise Barringer,
Health Insurance Specialist, Department
of Health and Human Services, Centers
for Medicare & Medicaid Services,
Center for Medicare, MS: C4–03–06,
7500 Security Boulevard, Baltimore, MD
21244, Phone: 410 786–9222, Email:
elise.barringer@cms.hhs.gov.
RIN: 0938–AV35
PO 00000
Frm 00009
Fmt 4701
Sfmt 4702
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Centers for Medicare & Medicaid
Services (CMS)
Final Rule Stage
341. CY 2024 Revisions To Payment
Policies Under the Physician Fee
Schedule and Other Revisions to
Medicare Part B (CMS–1784) (Section
610 Review) [0938–AV07]
Legal Authority: 42 U.S.C. 1395hh; 42
U.S.C. 1302
Abstract: This annual final rule
revises payment polices under the
Medicare physician fee schedule, and
makes other policy changes to payment
under Medicare Part B including, but
not limited to, establishing payment
policies for dental services prior to the
initiation of immunotherapy services.
These changes apply to services
furnished beginning January 1, 2024.
Additionally, this rule updates the
Quality Payment Program.
Timetable:
Action
NPRM ..................
NPRM Comment
Period End.
Final Action .........
Date
08/07/23
09/11/23
FR Cite
88 FR 52262
01/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Gift Tee, Director,
Division of Physician Services,
Department of Health and Human
Services, Centers for Medicare &
Medicaid Services, Center for Medicare,
7500 Security Boulevard, MS: C1–09–
07, Baltimore, MD 21244, Phone: 410
786–9316, Email: gift.tee@cms.hhs.gov.
RIN: 0938–AV07
342. CY 2024 Hospital Outpatient PPS
Policy Changes and Payment Rates and
Ambulatory Surgical Center Payment
System Policy Changes and Payment
Rates (CMS–1786) (Section 610 Review)
[0938–AV09]
Legal Authority: 42 U.S.C. 1395hh; 42
U.S.C. 1302
Abstract: This annual final rule
revises the Medicare hospital outpatient
prospective payment system to
implement statutory requirements and
changes arising from our continuing
experience with this system. The rule
describes changes to the amounts and
factors used to determine payment rates
for services. In addition, the rule makes
changes to the ambulatory surgical
center payment system list of services
and rates. This rule also updates and
refines the requirements for the Hospital
Outpatient Quality Reporting (OQR)
E:\FR\FM\09FEP8.SGM
09FEP8
9586
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
Program and the ASC Quality Reporting
(ASCQR) Program.
Timetable:
Action
Date
NPRM ..................
NPRM Comment
Period End.
Final Action .........
07/31/23
09/11/23
FR Cite
88 FR 49552
01/00/24
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Elise Barringer,
Health Insurance Specialist, Department
of Health and Human Services, Centers
for Medicare & Medicaid Services,
Center for Medicare, MS: C4–03–06,
7500 Security Boulevard, Baltimore, MD
21244, Phone: 410 786–9222, Email:
elise.barringer@cms.hhs.gov.
RIN: 0938–AV09
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Centers for Medicare & Medicaid
Services (CMS)
Completed Actions
343. FY 2024 Skilled Nursing Facility
(SNF) PPS and Consolidated Billing and
Updates to the Value-Based Purchasing
and Quality Reporting Programs (CMS–
1779) (Completion of a Section 610
Review) [0938–AV02]
Legal Authority: 42 U.S.C. 1395hh; 42
U.S.C. 1302
Abstract: This annual final rule
updates the payment rates used under
the prospective payment system for
SNFs for fiscal year 2024. The rule also
includes changes for the SNF Quality
Reporting Program (QRP) and for the
Skilled Nursing Facility Value-Based
Purchasing (VBP) Program that will
affect Medicare payment to SNFs.
Timetable:
Action
Date
ddrumheller on DSK120RN23PROD with PROPOSALS8
NPRM ..................
NPRM Comment
Period End.
Final Action .........
Final Action Effective.
FR Cite
04/10/23
06/05/23
88 FR 21316
08/07/23
10/01/23
88 FR 53200
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Tammy Luo, Health
Insurance Specialist, Department of
Health and Human Services, Centers for
Medicare & Medicaid Services, Center
for Medicare, MS: C5–06–17, 7500
Security Boulevard, Baltimore, MD
21244, Phone: 410 786–4325, Email:
tammy.luo@cms.hhs.gov.
RIN: 0938–AV02
VerDate Sep<11>2014
20:53 Feb 08, 2024
Jkt 262001
344. CY 2024 Home Health Prospective
Payment System Rate Update and
Home Infusion Therapy Services
Payment Update (CMS–1780)
(Completion of a Section 610 Review)
[0938–AV03]
Legal Authority: 42 U.S.C. 1302; 42
U.S.C. 1395(fff); 42 U.S.C. 1395(m)
Abstract: This annual final rule
updates the national, standardized 30day period payment rate, national pervisit rates used to calculate low
utilization payment adjustments
(LUPAs) and outlier payments under the
Medicare prospective payment system
for home health agencies based on the
applicable home health payment update
percentage. Additionally, this rule
updates payment rates for home
infusion therapy services and makes
changes to the Medicare enrollment
requirements for hospices. These
changes apply to services furnished on
or after January 1, 2024. This rule also
makes changes to how the separate
payment for negative pressure wound
therapy using a disposable device is
made as required by section 4136 of the
Consolidated Appropriations Act of
2023 (CAA, 2023), and implements the
permanent home intravenous immune
globulin services (IVIG) benefit as
required by section 4134 of the CAA,
2023. This rule addresses the scope of
the Medicare Part B benefit for leg, arm,
back, and neck braces under section
1861(s)(9) of the Social Security Act,
and newer technology devices, as well
as the implementation of the Medicare
Part B benefit for lymphedema
compression treatment items under
section 1861(s)(2) of the Social Security
Act.
Timetable:
Action
Date
NPRM ..................
NPRM Comment
Period End.
Final Action .........
Final Action Effective.
FR Cite
07/10/23
08/29/23
88 FR 43654
11/13/23
01/01/24
88 FR 77676
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Brian Slater,
Director, Division of Home Health and
Hospice, Department of Health and
Human Services, Centers for Medicare &
Medicaid Services, Center for Medicare,
MS: C4–07–07, 7500 Security
Boulevard, Baltimore, MD 21244,
Phone: 410 786–5229, Email:
brian.slater@cms.hhs.gov.
RIN: 0938–AV03
PO 00000
Frm 00010
Fmt 4701
Sfmt 4702
345. FY 2024 Inpatient Psychiatric
Facilities Prospective Payment System
Rate and Quality Reporting Updates
(CMS–1783) (Completion of a Section
610 Review) [0938–AV06]
Legal Authority: 42 U.S.C. 1302; 42
U.S.C. 1395f; 42 U.S.C. 1395g; 42 U.S.C.
1395hh; . . .
Abstract: This annual final rule
updates the prospective payment system
for inpatient psychiatric facilities (IPF)
with discharges beginning on October 1,
2023. The rule also includes updates to
the IPF Quality Reporting Program.
Timetable:
Action
NPRM ..................
NPRM Comment
Period End.
Final Action .........
Final Action Effective.
Date
FR Cite
04/10/23
06/05/23
88 FR 21238
08/02/23
10/01/23
88 FR 51054
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Nicolas Brock,
Health Insurance Specialist, Department
of Health and Human Services, Centers
for Medicare & Medicaid Services,
Center for Medicare, MS: C5–05–27,
7500 Security Boulevard, Baltimore, MD
21244, Phone: 410 786–5148, Email:
nicolas.brock@cms.hhs.gov.
RIN: 0938–AV06
346. Hospital Inpatient Prospective
Payment Systems for Acute Care
Hospitals; the Long-Term Care Hospital
Prospective Payment System; and FY
2024 Rates (CMS–1785) (Completion of
a Section 610 Review) [0938–AV08]
Legal Authority: 42 U.S.C. 1395hh; 42
U.S.C. 1302
Abstract: This annual final rule
revises the Medicare hospital inpatient
and long-term care hospital prospective
payment systems for operating and
capital-related costs. This rule
implements changes arising from our
continuing experience with these
systems. In addition, the rule establishes
new requirements or revises existing
requirements for quality reporting by
specific Medicare providers.
Timetable:
Action
NPRM ..................
NPRM Comment
Period End.
Final Action .........
Final Action Effective.
Date
FR Cite
05/01/23
06/09/23
88 FR 26658
08/28/23
10/01/23
88 FR 58640
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Donald Thompson,
Director, Division of Acute Care,
E:\FR\FM\09FEP8.SGM
09FEP8
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / UA: Reg Flex Agenda
Department of Health and Human
Services, Centers for Medicare &
Medicaid Services, Center for Medicare,
MS: C4–01–26, 7500 Security
Boulevard, Baltimore, MD 21244,
Phone: 410 786–6504, Email:
donald.thompson@cms.hhs.gov.
RIN: 0938–AV08
347. FY 2024 Hospice Wage Index,
Payment Rate Update, and Quality
Reporting Requirements (CMS–1787)
(Completion of a Section 610 Review)
[0938–AV10]
Legal Authority: 42 U.S.C. 1302; 42
U.S.C. 1395hh
Abstract: This annual final rule
updates the hospice payment rates and
the wage index for fiscal year 2024. The
rule also finalizes changes to the
Hospice Quality Reporting program.
Timetable:
Action
Date
ddrumheller on DSK120RN23PROD with PROPOSALS8
NPRM ..................
NPRM Comment
Period End.
VerDate Sep<11>2014
I
04/04/23
05/30/23
20:53 Feb 08, 2024
FR Cite
88 FR 20022
I
Jkt 262001
Action
Date
Final Action .........
Final Action Effective.
FR Cite
08/02/23
10/01/23
I
88 FR 51164
I
Regulatory Flexibility Analysis
Required: Yes.
Agency Contact: Brian Slater,
Director, Division of Home Health and
Hospice, Department of Health and
Human Services, Centers for Medicare &
Medicaid Services, Center for Medicare,
MS: C4–07–07, 7500 Security
Boulevard, Baltimore, MD 21244,
Phone: 410 786–5229, Email:
brian.slater@cms.hhs.gov.
RIN: 0938–AV10
348. Hospital Outpatient Prospective
Payment System: Remedy for 340BAcquired Drugs Purchased in Cost
Years 2018–2022 (CMS–1793) (Section
610 Review) [0938–AV18]
Regulatory Plan: This entry is Seq.
No. 77 in part II of this issue of the
Federal Register.
RIN: 0938–AV18
PO 00000
Frm 00011
Fmt 4701
Sfmt 9990
9587
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Administration for Children and
Families (ACF)
Proposed Rule Stage
349. Supporting the Head Start
Workforce and Other Quality
Improvements [0970–AD01]
Regulatory Plan: This entry is Seq.
No. 80 in part II of this issue of the
Federal Register.
RIN: 0970–AD01
350. • Safe and Appropriate Foster Care
Placement Requirements for Titles IV–
E and IV–B (Section 610 Review) [0970–
AD03]
Regulatory Plan: This entry is Seq.
No. 81 in part II of this issue of the
Federal Register.
RIN: 0970–AD03
[FR Doc. 2024–00453 Filed 2–8–24; 8:45 am]
BILLING CODE 4150–03–P
E:\FR\FM\09FEP8.SGM
09FEP8
Agencies
[Federal Register Volume 89, Number 28 (Friday, February 9, 2024)]
[Unknown Section]
[Pages 9578-9587]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00453]
[[Page 9577]]
Vol. 89
Friday,
No. 28
February 9, 2024
Part VIII
Department of Health and Human Services
-----------------------------------------------------------------------
Semiannual Regulatory Agenda
Federal Register / Vol. 89 , No. 28 / Friday, February 9, 2024 / UA:
Reg Flex Agenda
[[Page 9578]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
21 CFR Ch. I
25 CFR Ch. V
42 CFR Chs. I-V
45 CFR Subtitle A; Subtitle B, Chs. II, III, and XIII
Regulatory Agenda
AGENCY: Office of the Secretary, HHS.
ACTION: Semiannual Regulatory Agenda.
-----------------------------------------------------------------------
SUMMARY: The Regulatory Flexibility Act of 1980 and Executive Order
(E.O.) 12866 require the semiannual issuance of an inventory of
rulemaking actions under development throughout the Department,
offering for public review summarized information about forthcoming
regulatory actions.
FOR FURTHER INFORMATION CONTACT: Elizabeth J. Gramling, Executive
Secretary, Department of Health and Human Services, 200 Independence
Avenue SW, Washington, DC 20201; (202) 690-5627.
SUPPLEMENTARY INFORMATION: The Department of Health and Human Services
(HHS) is the Federal government's lead agency for protecting the health
of all Americans and providing essential human services. HHS enhances
the health and well-being of Americans by promoting effective health
and human services and by fostering sound, sustained advances in the
sciences underlying medicine, public health, and social services.
This Agenda presents the regulatory activities that the Department
expects to undertake in the foreseeable future to advance this mission.
The purpose of the Agenda is to encourage more effective public
participation in the regulatory process. The regulatory actions
forecasted in this Agenda reflect the priorities of HHS Secretary
Xavier Becerra and the Biden-Harris Administration. Accordingly, this
Agenda contains rulemakings aimed at ensuring that the nation is well-
prepared to manage COVID-19 going forward, building and expanding
access to affordable, quality health care, addressing health
disparities and promoting equity, and boosting the mental health and
wellbeing of children and families, among other policy priorities.
The rulemaking abstracts included in this paper issue of the
Federal Register cover, as required by the Regulatory Flexibility Act
of 1980, those prospective HHS rulemakings likely to have a significant
economic impact on a substantial number of small entities. The
Department's complete Regulatory Agenda is accessible online at https://www.RegInfo.gov.
Elizabeth J. Gramling,
HHS Executive Secretary.
Office for Civil Rights--Proposed Rule Stage
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
313....................... Rulemaking on 0945-AA15
Discrimination on the
Basis of Disability in
Health and Human Services
Programs or Activities
(Reg Plan Seq No. 48).
------------------------------------------------------------------------
References in boldface appear in The Regulatory Plan in part II of this
issue of the Federal Register.
Substance Abuse and Mental Health Services Administration--Final Rule
Stage
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
314....................... Medications for the 0930-AA39
Treatment of Opioid Use
Disorder.
------------------------------------------------------------------------
Centers for Disease Control and Prevention--Final Rule Stage
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
315....................... Control of Communicable 0920-AA75
Diseases; Foreign
Quarantine (Reg Plan Seq
No. 56).
------------------------------------------------------------------------
References in boldface appear in The Regulatory Plan in part II of this
issue of the Federal Register.
Food and Drug Administration--Proposed Rule Stage
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
316....................... Medication Guide; Patient 0910-AH68
Medication Information.
317....................... Administrative Detention 0910-AI05
of Tobacco Products.
318....................... Conduct of Analytical and 0910-AI57
Clinical Pharmacology,
Bioavailability, and
Bioequivalence Studies.
319....................... Amendments to the Final 0910-AI70
Rule Regarding the List
of Bulk Substances That
Can Be Used to Compound
Drug Products in
Accordance With Section
503A of the Federal Food,
Drug, and Cosmetic Act
(Section 610 Review).
320....................... Distribution of Compounded 0910-AI71
Drug Products Under
Section 503A of the
Federal Food, Drug, and
Cosmetic Act (Section 610
Review).
321....................... Tobacco Product Standard 0910-AI76
for Nicotine Level of
Certain Tobacco Products
(Reg Plan Seq No. 57).
322....................... Front-of-Package Nutrition 0910-AI80
Labeling (Reg Plan Seq
No. 58).
323....................... Medical Devices; 0910-AI85
Laboratory Developed
Tests (Reg Plan Seq No.
59).
324....................... Registration of Commercial 0910-AI87
Importers of Drugs; Good
Importing Practice.
------------------------------------------------------------------------
References in boldface appear in The Regulatory Plan in part II of this
issue of the Federal Register.
[[Page 9579]]
Food and Drug Administration--Final Rule Stage
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
325....................... Direct-to-Consumer 0910-AG27
Prescription Drug
Advertisements:
Presentation of the Major
Statement in a Clear,
Conspicuous, Neutral
Manner in Advertisements
in Television and Radio
Format.
326....................... Sunlamp Products; 0910-AG30
Amendment to the
Performance Standard.
327....................... General and Plastic 0910-AH14
Surgery Devices:
Restricted Sale,
Distribution, and Use of
Sunlamp Products.
328....................... Amendments to the List of 0910-AH81
Bulk Drug Substances That
Can Be Used To Compound
Drug Products in
Accordance With Section
503A of the Federal Food,
Drug, and Cosmetic Act.
329....................... Requirements for Tobacco 0910-AH91
Product Manufacturing
Practice.
330....................... Nutrient Content Claims, 0910-AI13
Definition of Term:
Healthy (Reg Plan Seq No.
61).
331....................... Tobacco Product Standard 0910-AI28
for Characterizing
Flavors in Cigars (Reg
Plan Seq No. 62).
332....................... Tobacco Product Standard 0910-AI60
for Menthol in Cigarettes
(Reg Plan Seq No. 64).
------------------------------------------------------------------------
References in boldface appear in The Regulatory Plan in part II of this
issue of the Federal Register.
Food and Drug Administration--Long-Term Actions
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
333....................... National Standards for the 0910-AH11
Licensure of Wholesale
Drug Distributors and
Third-Party Logistics
Providers.
334....................... Nicotine Toxicity Warnings 0910-AH24
335....................... Certain Requirements 0910-AH56
Regarding Prescription
Drug Marketing (203
Amendment).
336....................... Postmarketing Safety 0910-AI61
Reporting Requirements,
Pharmacovigilance Plans,
and Pharmacovigilance
Quality Systems for Human
Drug and Biological
Products.
------------------------------------------------------------------------
Food and Drug Administration--Completed Actions
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
337....................... Revocation of Uses of 0910-AI15
Partially Hydrogenated
Oils in Foods.
------------------------------------------------------------------------
Centers for Medicare & Medicaid Services--Proposed Rule Stage
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
338....................... CY 2025 Revisions to 0938-AV33
Payment Policies Under
the Physician Fee
Schedule and Other
Revisions to Medicare
Part B (CMS-1807)
(Section 610 Review).
339....................... Hospital Inpatient 0938-AV34
Prospective Payment
Systems for Acute Care
Hospitals; the Long-Term
Care Hospital Prospective
Payment System; and FY
2025 Rates (CMS-1808)
(Section 610 Review).
340....................... CY 2025 Hospital 0938-AV35
Outpatient PPS Policy
Changes and Payment Rates
and Ambulatory Surgical
Center Payment System
Policy Changes and
Payment Rates (CMS-1809)
(Section 610 Review).
------------------------------------------------------------------------
Centers for Medicare & Medicaid Services--Final Rule Stage
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
341....................... CY 2024 Revisions to 0938-AV07
Payment Policies Under
the Physician Fee
Schedule and Other
Revisions to Medicare
Part B (CMS-1784)
(Section 610 Review).
342....................... CY 2024 Hospital 0938-AV09
Outpatient PPS Policy
Changes and Payment Rates
and Ambulatory Surgical
Center Payment System
Policy Changes and
Payment Rates (CMS-1786)
(Section 610 Review).
------------------------------------------------------------------------
Centers for Medicare & Medicaid Services--Completed Actions
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
343....................... FY 2024 Skilled Nursing 0938-AV02
Facility (SNF) PPS and
Consolidated Billing and
Updates to the Value-
Based Purchasing and
Quality Reporting
Programs (CMS-1779)
(Completion of a Section
610 Review).
344....................... CY 2024 Home Health 0938-AV03
Prospective Payment
System Rate Update and
Home Infusion Therapy
Services Payment Update
(CMS-1780) (Completion of
a Section 610 Review).
345....................... FY 2024 Inpatient 0938-AV06
Psychiatric Facilities
Prospective Payment
System Rate and Quality
Reporting Updates (CMS-
1783) (Completion of a
Section 610 Review).
346....................... Hospital Inpatient 0938-AV08
Prospective Payment
Systems for Acute Care
Hospitals; the Long-Term
Care Hospital Prospective
Payment System; and FY
2024 Rates (CMS-1785)
(Completion of a Section
610 Review).
[[Page 9580]]
347....................... FY 2024 Hospice Wage 0938-AV10
Index, Payment Rate
Update, and Quality
Reporting Requirements
(CMS-1787) (Completion of
a Section 610 Review).
348....................... Hospital Outpatient 0938-AV18
Prospective Payment
System: Remedy for 340B-
Acquired Drugs Purchased
in Cost Years 2018-2022
(CMS-1793) (Section 610
Review) (Reg Plan Seq No.
77).
------------------------------------------------------------------------
References in boldface appear in The Regulatory Plan in part II of this
issue of the Federal Register.
Administration for Children and Families--Proposed Rule Stage
------------------------------------------------------------------------
Regulation
Sequence No. Title Identifier No.
------------------------------------------------------------------------
349....................... Supporting the Head Start 0970-AD01
Workforce and Other
Quality Improvements (Reg
Plan Seq No. 80).
350....................... Safe and Appropriate 0970-AD03
Foster Care Placement
Requirements for Titles
IV-E and IV-B (Section
610 Review) (Reg Plan Seq
No. 81).
------------------------------------------------------------------------
References in boldface appear in The Regulatory Plan in part II of this
issue of the Federal Register.
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Office for Civil Rights (OCR)
Proposed Rule Stage
313. Rulemaking on Discrimination on the Basis of Disability in Health
and Human Services Programs or Activities [0945-AA15]
Regulatory Plan: This entry is Seq. No. 48 in part II of this issue
of the Federal Register.
RIN: 0945-AA15
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Substance Abuse and Mental Health Services Administration (SAMHSA)
Final Rule Stage
314. Medications for the Treatment of Opioid Use Disorder [0930-AA39]
Legal Authority: 21 U.S.C. 823(g)(1)
Abstract: The Substance Abuse and Mental Health Services
Administration (SAMHSA) will revise 42 CFR part 8 to make permanent
some regulatory flexibilities for Opioid Treatment Programs (OTPs)
granted under the COVID-19 Public Health Emergency (PHE), and to expand
access to care for people with Opioid Use Disorder (OUD). Specifically,
SAMHSA will update criteria pertaining to unsupervised doses of
methadone and also initiation of buprenorphine via telemedicine. To
expand access to care, SAMHSA will also update admission criteria,
particularly those rules that may limit timely access to treatment in
an OTP. To achieve this, sections of 42 CFR part 8 will require
updating. SAMHSA's changes will impact roughly 1900 opioid treatment
programs and state opioid treatment authorities.
In response to the Consolidated Appropriations Act of 2023, which
removed the requirement to obtain a waiver in order to prescribe
certain schedule III-V medications for the treatment of OUD, SAMHSA
issued a supplemental notice of proposed rulemaking on Feb. 13, 2023,
(88 FR 9221) calling for additional public comment on SAMHSA's plans to
remove reference to the Drug Addiction Treatment Act of 2000 (DATA
2000-Waiver) from 42 CFR part 8.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 12/16/22 87 FR 77330
Supplemental NPRM................... 02/13/23 88 FR 9221
NPRM Comment Period End............. 02/14/23
Supplemental NPRM Comment Period End 03/14/23
Final Action........................ 01/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Dr. Neeraj Gandotra, Chief Medical Officer,
Department of Health and Human Services, Substance Abuse and Mental
Health Services Administration, 5600 Fishers Lane, 18E67, Rockville, MD
20857, Phone: 202 823-1816, Email: [email protected].
RIN: 0930-AA39
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Centers for Disease Control and Prevention (CDC)
Final Rule Stage
315. Control of Communicable Diseases; Foreign Quarantine [0920-AA75]
Regulatory Plan: This entry is Seq. No. 56 in part II of this issue
of the Federal Register.
RIN: 0920-AA75
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Food and Drug Administration (FDA)
Proposed Rule Stage
316. Medication Guide; Patient Medication Information [0910-AH68]
Legal Authority: 21 U.S.C. 321 et seq.; 42 U.S.C. 262; 42 U.S.C.
264; 21 U.S.C. 371
Abstract: The rule will amend FDA medication guide regulations to
require a new form of patient labeling, namely Patient Medication
Information, for submission to and review by FDA for human prescription
drug products and certain blood products used, dispensed, or
administered on an outpatient basis. The rule will include requirements
for the development and distribution of Patient Medication Information.
The rule will require clear and concisely written prescription drug
product information presented in a consistent and easily understood
format to help patients use their prescription drug products safely and
effectively.
Timetable:
[[Page 9581]]
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 05/31/23 88 FR 35694
NPRM Comment Period End............. 11/27/23
Final Action........................ 03/00/26
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Chris Wheeler, Supervisory Project Manager,
Department of Health and Human Services, Food and Drug Administration,
10903 New Hampshire Avenue, Building 51, Room 3330, Silver Spring, MD
20993, Phone: 301 796-0151, Email: [email protected].
RIN: 0910-AH68
317. Administrative Detention of Tobacco Products [0910-AI05]
Legal Authority: 21 U.S.C. 334; 21 U.S.C. 371
Abstract: FDA is proposing a regulation to establish requirements
for the administrative detention of tobacco products. This proposed
rule, when finalized, would allow FDA to administratively detain
tobacco products encountered during inspections of manufacturers or
other establishments that manufacture, process, pack, or hold tobacco
products that an authorized FDA representative conducting the
inspection has reason to believe are adulterated or misbranded. The
intent of administrative detention is to protect public health by
preventing the distribution or use of tobacco products encountered
during inspections that are believed to be adulterated or misbranded
until FDA has had time to consider the appropriate action to take and,
where appropriate, to initiate legal action.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 10/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Quynh Nguyen, Regulatory Counsel, Department of
Health and Human Services, Food and Drug Administration, Center for
Tobacco Products, 10903 New Hampshire Avenue, Document Control Center,
Building 71, Room G335, Silver Spring, MD 20993, Phone: 877 287-1373,
Email: [email protected].
Laura Chilaka, Regulatory Counsel, Department of Health and Human
Services, Food and Drug Administration, Center for Tobacco Products,
10903 New Hampshire Avenue, Document Control Center, Building 71, Room
G335, Silver Spring, MD 20993, Phone: 877 287-1373, Email:
[email protected].
RIN: 0910-AI05
318. Conduct of Analytical and Clinical Pharmacology, Bioavailability,
and Bioequivalence Studies [0910-AI57]
Legal Authority: 21 U.S.C. 355; 21 U.S.C. 371; 21 U.S.C. 374; 42
U.S.C. 262
Abstract: FDA is proposing to amend 21 CFR 320, in certain parts,
and establish a new 21 CFR 321 to clarify FDA's study conduct
expectations for clinical pharmacology, and clinical and analytical
bioavailability (BA) and bioequivalence (BE) studies that support
marketing applications for human drug and biological products. The
proposed rule would specify needed basic study conduct requirements to
enable FDA to ensure those studies are conducted appropriately and to
verify the reliability of study data from those studies. This
regulation would align with FDA's other good practice regulations,
would also be consistent with current industry best practices, and
would harmonize the regulations more closely with related international
regulatory expectations.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 04/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Brian Joseph Folian, Supervisory Biologist,
Department of Health and Human Services, Food and Drug Administration,
10903 New Hampshire Avenue, Building 51, Room 5215, Silver Spring, MD
20993-0002, Phone: 240 402-4089, Email: [email protected].
RIN: 0910-AI57
319. Amendments to the Final Rule Regarding the List of Bulk Substances
That Can Be Used To Compound Drug Products in Accordance With Section
503A of the Federal Food, Drug, and Cosmetic Act (Section 610 Review)
[0910-AI70]
Legal Authority: 21 U.S.C. 353a; 21 U.S.C. 351; 21 U.S.C. 371(a);
21 U.S.C. 352; 21 U.S.C. 355
Abstract: FDA has issued a regulation creating a list of bulk drug
substances (active pharmaceutical ingredients) that can be used to
compound drug products in accordance with section 503A of the Federal
Food, Drug, and Cosmetic Act, although they are neither the subject of
an applicable United States Pharmacopeia (USP) or National Formulary
(NF) monograph nor components of FDA-approved drug products (the 503A
Bulks List). The proposed rule will identify certain bulk drug
substances that FDA has considered and is proposing to place on the
503A Bulks List and certain bulk drug substances that FDA has
considered and is proposing not to include on the 503A Bulks List.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 10/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Rosilend Lawson, Regulatory Counsel, Department of
Health and Human Services, Food and Drug Administration, 10903 New
Hampshire Avenue, Building 51, Room 5197, Silver Spring, MD 20993,
Phone: 240 402-6223, Email: [email protected].
RIN: 0910-AI70
320. Distribution of Compounded Drug Products Under Section 503A of the
Federal Food, Drug, and Cosmetic Act (Section 610 Review) [0910-AI71]
Legal Authority: 21 U.S.C. 351; 21 U.S.C. 352; 21 U.S.C. 353a; 21
U.S.C. 353a-1; 21 U.S.C. 355; 21 U.S.C. 371
Abstract: The Food and Drug Administration is proposing rulemaking
regarding statutory requirements under section 503A of the Federal
Food, Drug, and Cosmetic Act for certain distributions of compounded
human drug products. The proposed rule, if finalized, will include
provisions regarding a standard memorandum of understanding (MOU) that
describes the responsibilities of a State Board of Pharmacy or other
appropriate State agency that chooses to sign the standard MOU in
investigating complaints related to drug products compounded in such
State and distributed outside such State and in addressing the
interstate distribution of inordinate amounts of compounded human drug
products. It will also, if finalized, include provisions regarding the
statutory 5 percent limit on distribution of compounded human drug
products out of the State in which they are compounded in States that
do not sign the standard MOU. The rule, will also, if finalized,
address communication with State boards of pharmacy.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 12/00/23
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
[[Page 9582]]
Agency Contact: Dominic Markwordt, Regulatory Counsel, Department
of Health and Human Services, Food and Drug Administration, Center for
Drug Evaluation and Research, 10903 New Hampshire Avenue, Building 51,
Room 5104, Silver Spring, MD 20993, Phone: 301 796-9349, Email:
[email protected].
RIN: 0910-AI71
321. Tobacco Product Standard for Nicotine Level of Certain Tobacco
Products [0910-AI76]
Regulatory Plan: This entry is Seq. No. 57 in part II of this issue
of the Federal Register.
RIN: 0910-AI76
322. Front-of-Package Nutrition Labeling [0910-AI80]
Regulatory Plan: This entry is Seq. No. 58 in part II of this issue
of the Federal Register.
RIN: 0910-AI80
323. Medical Devices; Laboratory Developed Tests [0910-AI85]
Regulatory Plan: This entry is Seq. No. 59 in part II of this issue
of the Federal Register.
RIN: 0910-AI85
324. Registration of Commercial Importers of Drugs; Good Importing
Practice [0910-AI87]
Legal Authority: sec. 714 of the Food and Drug Administrative
Safety and Innovation Act (FDASIA) of July 2012
Abstract: This proposed rulemaking meets the mandate of section 714
of the Food and Drug Administration Safety and Innovation Act and will
establish registration and good importing practice requirements for
commercial importers of drugs. Although manufacturers are subject to
regulatory requirements to ensure such quality standards are met, there
are few clear responsibilities for commercial importers of drugs to do
the same.
Cost estimates of the rule include reading and understanding the
rule, registering as a commercial importer through the Food and Drug
Administration's (FDA) electronic importer registration system, annual
updating of registration, establishing a quality management system,
conducting risk evaluations of drugs and suppliers, shipment
verifications, investigations, corrective actions, and records
maintenance.
The unquantified benefits of the proposed rule include improvement
in the safety of finished drugs allowed to enter the United States from
the commercial drug importer's requirement to register with FDA and for
increased due diligence required by the importer regarding the safety
of the drugs. There would also be cost savings to both FDA and industry
from facilitating the review of documentation that ensures compliance
with our regulations prior to being allowed to enter the United States.
This proposed rulemaking will also enhance FDA's ability to collect and
analyze data to enable risk-informed decision-making while focusing on
protecting the integrity of the global drug supply chain and ensuring
safety, effectiveness, and quality of imported drugs.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 01/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: James Hanratty, Regulatory Counsel, Department of
Health and Human Services, Food and Drug Administration, WO 75, Rm.
1607A, 10903 New Hampshire Avenue, Silver Spring, MD 20993, Phone: 240
402-4718, Email: [email protected].
RIN: 0910-AI87
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Food and Drug Administration (FDA)
Final Rule Stage
325. Direct-to-Consumer Prescription Drug Advertisements: Presentation
of the Major Statement in a Clear, Conspicuous, Neutral Manner in
Advertisements in Television and Radio Format [0910-AG27]
Legal Authority: 21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 352; 21
U.S.C. 355; 21 U.S.C. 360b; 21 U.S.C. 371; . . .
Abstract: The Food and Drug Administration (FDA) is amending its
regulations concerning direct-to-consumer (DTC) advertisements of
prescription drugs. Prescription drug advertisements presented through
media such as TV and radio must disclose the product's major side
effects and contraindications in what is sometimes called the major
statement. The rule would revise the regulation to reflect the
statutory requirement that in DTC advertisements for human prescription
drugs presented in television or radio format and stating the name of
the drug and its conditions of use, the major statement relating to
side effects and contraindications of the advertised drug must be
presented in a clear, conspicuous, and neutral manner. This rule also
establishes standards for determining whether the major statement in
these advertisements is presented in the manner required.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 03/29/10 75 FR 15376
NPRM Comment Period End............. 06/28/10
NPRM Comment Period Reopened........ 01/27/12 77 FR 4273
NPRM Comment Period End............. 02/27/12
NPRM Comment Period Reopened........ 03/29/12 77 FR 16973
NPRM Comment Period Reopened End.... 04/09/12
Final Rule.......................... 11/00/23
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Suzanna Boyle, Regulatory Counsel, Department of
Health and Human Services, Food and Drug Administration, 10903 New
Hampshire Avenue, WO 51, Room 3214, Silver Spring, MD 20993, Phone: 240
402-4723, Email: [email protected].
RIN: 0910-AG27
326. Sunlamp Products; Amendment to the Performance Standard [0910-
AG30]
Legal Authority: 21 U.S.C. 360ii; 21 U.S.C. 360kk; 21 U.S.C. 393;
21 U.S.C. 371
Abstract: FDA is updating the performance standard for sunlamp
products and ultraviolet lamps intended for use in these products to
improve safety, reflect new scientific information, and work towards
harmonization with international standards. By harmonizing with the
International Electrotechnical Commission, this rule will decrease the
regulatory burden on industry and allow the Agency to take advantage of
the expertise of the international committees, thereby also saving
resources.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 12/22/15 80 FR 79505
NPRM Comment Period End............. 03/21/16
Final Rule.......................... 03/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Ian Ostermiller, Regulatory Counsel, Center for
Devices and Radiological Health, Department of Health and Human
Services, Food and
[[Page 9583]]
Drug Administration, 10903 New Hampshire Avenue, WO 66, Room 5454,
Silver Spring, MD 20993, Phone: 301 796-5678, Email:
[email protected].
RIN: 0910-AG30
327. General and Plastic Surgery Devices: Restricted Sale,
Distribution, and Use of Sunlamp Products [0910-AH14]
Legal Authority: 21 U.S.C. 360j(e)
Abstract: This rule will apply device restrictions to sunlamp
products. Sunlamp products include ultraviolet (UV) lamps and UV
tanning beds and booths. The incidence of skin cancer, including
melanoma, has been increasing, and a large number of skin cancer cases
are attributable to the use of sunlamp products. The devices may cause
about 400,000 cases of skin cancer per year, and 6,000 of which are
melanoma. Beginning use of sunlamp products at young ages, as well as
frequently using sunlamp products, both increases the risk of
developing skin cancers and other illnesses, and sustaining other
injuries. Even infrequent use, particularly at younger ages, can
significantly increase these risks.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 12/22/15 80 FR 79493
NPRM Comment Period End............. 03/21/16
Final Rule.......................... 03/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Daniel Schieffer, Regulatory Counsel, Department of
Health and Human Services, Food and Drug Administration, Center for
Devices and Radiological Health, 10903 New Hampshire Avenue, WO 75,
Room 7613, Silver Spring, MD 20993, Phone: 301 796-3350, Email:
[email protected].
RIN: 0910-AH14
328. Amendments to the List of Bulk Drug Substances That Can Be Used To
Compound Drug Products in Accordance With Section 503A of the Federal
Food, Drug, and Cosmetic Act [0910-AH81]
Legal Authority: 21 U.S.C. 351; 21 U.S.C. 352; 21 U.S.C. 353a; 21
U.S.C. 355; 21 U.S.C. 371
Abstract: FDA has issued a regulation creating a list of bulk drug
substances (active pharmaceutical ingredients) that can be used to
compound drug products in accordance with section 503A of the Federal
Food, Drug, and Cosmetic Act (FD&C Act), although they are neither the
subject of an applicable United States Pharmacopeia (USP) or National
Formulary (NF) monograph nor components of FDA-approved drugs (the 503A
Bulks List). FDA has proposed to amend the 503A Bulks List by placing
additional bulk drug substances on the list. FDA has also identified
bulk drug substances that FDA has considered and proposed not to
include on the 503A Bulks List. Additional substances nominated by the
public for inclusion on this list are currently under consideration and
will be the subject of future rulemaking.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 09/05/19 84 FR 46688
NPRM Comment Period End............. 12/04/19
Final Rule.......................... 10/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Rosilend Lawson, Regulatory Counsel, Department of
Health and Human Services, Food and Drug Administration, 10903 New
Hampshire Avenue, Building 51, Room 5197, Silver Spring, MD 20993,
Phone: 240 402-6223, Email: [email protected].
RIN: 0910-AH81
329. Requirements for Tobacco Product Manufacturing Practice [0910-
AH91]
Legal Authority: 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 381(a); 21
U.S.C. 387b; 21 U.S.C. 387c; 21 U.S.C. 387f; 21 U.S.C. 387i; . . .
Abstract: The rule would establish tobacco product manufacturing
practice (TPMP) requirements for manufacturers of finished and bulk
tobacco products. This rule, if finalized, would set forth requirements
for the manufacture, pre-production design validation, packing, and
storage of a tobacco product. This rule would help prevent the
manufacture and distribution of contaminated and otherwise
nonconforming tobacco products. This rule provides manufacturers with
flexibility in the manner in which they comply with the requirements
while giving FDA the ability to enforce regulatory requirements, thus
helping to assure the protection of public health.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 03/10/23 88 FR 15174
NPRM Comment Period End............. 09/06/23
NPRM Comment Period Extension to 08/29/23 88 FR 59481
Oct. 06, 2023.
Final Action........................ 10/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Matthew Brenner, Senior Regulatory Counsel,
Department of Health and Human Services, Food and Drug Administration,
Center for Tobacco Products, 10903 New Hampshire Avenue, Document
Control Center, Building 71, Room G335, Silver Spring, MD 20993, Phone:
877 287-1373, Email: [email protected].
RIN: 0910-AH91
330. Nutrient Content Claims, Definition of Term: Healthy [0910-AI13]
Regulatory Plan: This entry is Seq. No. 61 in part II of this issue
of the Federal Register.
RIN: 0910-AI13
331. Tobacco Product Standard for Characterizing Flavors in Cigars
[0910-AI28]
Regulatory Plan: This entry is Seq. No. 62 in part II of this issue
of the Federal Register.
RIN: 0910-AI28
332. Tobacco Product Standard for Menthol in Cigarettes [0910-AI60]
Regulatory Plan: This entry is Seq. No. 64 in part II of this issue
of the Federal Register.
RIN: 0910-AI60
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Food and Drug Administration (FDA)
Long-Term Actions
333. National Standards for the Licensure of Wholesale Drug
Distributors and Third-Party Logistics Providers [0910-AH11]
Legal Authority: secs. 583 and 584 of the FD&C Act, as added by the
DSCSA under Pub. L. 113-54, together with related FD&C Act authority
added by the DSCSA
Abstract: The final rule establishes national standards for State
licensing of prescription drug wholesale distributors and third-party
logistics providers. The rulemaking also establishes a Federal system
for wholesale drug distributor and third-party logistics provider
licensing for use in the absence of a State licensure program.
[[Page 9584]]
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 02/04/22 87 FR 6708
NPRM Comment Period End............. 06/06/22
NPRM Comment Period Extended........ 05/24/22 87 FR 31439
NPRM Comment Period Extended End.... 09/06/22
Final Rule.......................... 04/00/25
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Aaron Weisbuch, Regulatory Counsel, Department of
Health and Human Services, Food and Drug Administration, Center for
Drug Evaluation and Research, Building 51, Room 4261, 10903 New
Hampshire Avenue, Silver Spring, MD 20993, Phone: 301 796-9362, Email:
[email protected].
RIN: 0910-AH11
334. Nicotine Toxicity Warnings [0910-AH24]
Legal Authority: 21 U.S.C. 301 et seq.; 21 U.S.C. 331; 21 U.S.C.
371; 21 U.S.C. 387f; . . .
Abstract: This rule would establish acute nicotine toxicity warning
requirements for liquid nicotine and nicotine-containing e-liquid(s)
intended for human consumption, and potentially for other tobacco
products including, but not limited to, novel tobacco products such as
dissolvables, lotions, gels, and drinks. This action is intended to
increase consumer awareness and knowledge of the risks of acute
toxicity due to accidental nicotine exposure from nicotine-containing
e-liquids in tobacco products.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 04/00/25
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Laura Chilaka, Regulatory Counsel, Department of
Health and Human Services, Food and Drug Administration, Center for
Tobacco Products, 10903 New Hampshire Avenue, Document Control Center,
Building 71, Room G355, Silver Spring, MD 20993, Phone: 877 287-1373,
Email: [email protected].
RIN: 0910-AH24
335. Certain Requirements Regarding Prescription Drug Marketing (203
Amendment) [0910-AH56]
Legal Authority: Section 503 and related provisions of the FD&C
Act, as amended by Pub. L. 113-54
Abstract: The final rule amends Food and Drug Administration (FDA)
regulations at 21 CFR 203 to remove provisions no longer in effect and
incorporate conforming changes following enactment of the Drug Supply
Chain Security Act (DSCSA). The final rule amends the regulations to
clarify provisions and avoid causing confusion with the new standards
for wholesale distribution established by DSCSA.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 02/04/22 87 FR 6443
NPRM Comment Period End............. 04/05/22
Final Rule.......................... 04/00/25
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Aaron Weisbuch, Regulatory Counsel, Department of
Health and Human Services, Food and Drug Administration, Center for
Drug Evaluation and Research, Building 51, Room 4261, 10903 New
Hampshire Avenue, Silver Spring, MD 20993, Phone: 301 796-9362, Email:
[email protected].
RIN: 0910-AH56
336. Postmarketing Safety Reporting Requirements, Pharmacovigilance
Plans, and Pharmacovigilance Quality Systems for Human Drug and
Biological Products [0910-AI61]
Legal Authority: 42 U.S.C. 262; 42 U.S.C. 264; 42 U.S.C. 300aa-25;
21 U.S.C. 321; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21
U.S.C. 371; 21 U.S.C. 374; . . .
Abstract: The proposed rule would modernize FDA's regulations on
postmarketing safety reporting and pharmacovigilance for human drug and
biological products, including blood and blood components, by capturing
important new safety-related information, improving the quality and
utility of submitted reports, and supporting enhanced alignment with
internationally harmonized reporting guidelines. Among other things,
the proposed rule would require the submission of certain nonclinical
and clinical data to FDA in a periodic safety report, rather than the
annual report. The proposed rule also would require application holders
for drug products and certain biological products to establish and
maintain a pharmacovigilance quality system that reflects the
application holder's unique needs and that may support a more
streamlined, flexible approach to satisfying certain postmarketing
safety reporting requirements.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 10/00/25
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Janice L. Weiner, Principal Regulatory Counsel,
Department of Health and Human Services, Food and Drug Administration,
Center for Drug Evaluation and Research, 10903 New Hampshire Avenue,
Building 51, Room 6270, Silver Spring, MD 20993-0002, Phone: 301 796-
3475, Fax: 301 847-8440, Email: [email protected].
RIN: 0910-AI61
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Food and Drug Administration (FDA)
Completed Actions
337. Revocation of Uses of Partially Hydrogenated Oils in Foods [0910-
AI15]
Legal Authority: 21 U.S.C. 321; 21 U.S.C. 341; 21 U.S.C. 342; 21
U.S.C. 343; 21 U.S.C. 348; 21 U.S.C. 371; 21 U.S.C. 379e
Abstract: In the Federal Register of June 17, 2015 (80 FR 34650),
FDA published a declaratory order announcing our final determination
that there is no longer a consensus among qualified experts that
partially hydrogenated oils (PHOs) are generally recognized as safe
(GRAS) for any use in human food. In the Federal Register of May 21,
2018 (83 FR 23382), we denied a food additive petition requesting that
the food additive regulations be amended to provide for the safe use of
PHOs in certain food applications. Next, on August 9, 2023, we issued a
direct final rule and companion proposed rule that would update our
regulations to remove all mention of PHOs from FDA's GRAS regulations
and as an optional ingredient in standards of identity. This action
would also revoke all prior sanctions for uses of PHOs in food.
Completed:
------------------------------------------------------------------------
Reason Date FR Cite
------------------------------------------------------------------------
NPRM................................ 08/09/23 88 FR 53827
Direct Final Rule................... 08/09/23 88 FR 53764
[[Page 9585]]
Direct Final Rule Effective......... 12/22/23
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Ellen Anderson, Phone: 240 402-1309, Email:
[email protected].
RIN: 0910-AI15
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Centers for Medicare & Medicaid Services (CMS)
Proposed Rule Stage
338. CY 2025 Revisions To Payment Policies Under the Physician
Fee Schedule and Other Revisions to Medicare Part B (CMS-1807) (Section
610 Review) [0938-AV33]
Legal Authority: 42 U.S.C. 1302; 42 U.S.C. 1395hh; Pub. L. 117-169
Abstract: This annual proposed rule would revise payment polices
under the Medicare physician fee schedule, and make other policy
changes to payment under Medicare Part B. These changes would apply to
services furnished beginning January 1, 2025. Additionally, this rule
proposes updates to the Quality Payment Program. This proposed rule
would also codify the inflation rebate program for Medicare Part B and
Part D drugs established in the Inflation Reduction Act.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 06/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Gift Tee, Director, Division of Physician Services,
Department of Health and Human Services, Centers for Medicare &
Medicaid Services, Center for Medicare, 7500 Security Boulevard, MS:
C1-09-07, Baltimore, MD 21244, Phone: 410 786-9316, Email:
[email protected].
RIN: 0938-AV33
339. Hospital Inpatient Prospective Payment Systems for Acute
Care Hospitals; the Long-Term Care Hospital Prospective Payment System;
and FY 2025 Rates (CMS-1808) (Section 610 Review) [0938-AV34]
Legal Authority: 42 U.S.C. 1302; 42 U.S.C. 1395hh
Abstract: This annual proposed rule would revise the Medicare
hospital inpatient and long-term care hospital prospective payment
systems for operating and capital-related costs. This proposed rule
would implement changes arising from our continuing experience with
these systems. In addition, the rule proposes to establish new
requirements or revise existing requirements for quality reporting by
specific Medicare providers.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 04/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Donald Thompson, Director, Division of Acute Care,
Department of Health and Human Services, Centers for Medicare &
Medicaid Services, Center for Medicare, MS: C4-01-26, 7500 Security
Boulevard, Baltimore, MD 21244, Phone: 410 786-6504, Email:
[email protected].
RIN: 0938-AV34
340. CY 2025 Hospital Outpatient PPS Policy Changes and
Payment Rates and Ambulatory Surgical Center Payment System Policy
Changes and Payment Rates (CMS-1809) (Section 610 Review) [0938-AV35]
Legal Authority: 42 U.S.C. 1302; 42 U.S.C. 1395hh
Abstract: This annual proposed rule would revise the Medicare
hospital outpatient prospective payment system to implement statutory
requirements and changes arising from our continuing experience with
this system. The proposed rule describes changes to the amounts and
factors used to determine payment rates for services. In addition, the
rule proposes changes to the ambulatory surgical center payment system
list of services and rates. This proposed rule would also update and
refine the requirements for the Hospital Outpatient Quality Reporting
(OQR) Program and the ASC Quality Reporting (ASCQR) Program.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 06/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Elise Barringer, Health Insurance Specialist,
Department of Health and Human Services, Centers for Medicare &
Medicaid Services, Center for Medicare, MS: C4-03-06, 7500 Security
Boulevard, Baltimore, MD 21244, Phone: 410 786-9222, Email:
[email protected].
RIN: 0938-AV35
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Centers for Medicare & Medicaid Services (CMS)
Final Rule Stage
341. CY 2024 Revisions To Payment Policies Under the Physician Fee
Schedule and Other Revisions to Medicare Part B (CMS-1784) (Section 610
Review) [0938-AV07]
Legal Authority: 42 U.S.C. 1395hh; 42 U.S.C. 1302
Abstract: This annual final rule revises payment polices under the
Medicare physician fee schedule, and makes other policy changes to
payment under Medicare Part B including, but not limited to,
establishing payment policies for dental services prior to the
initiation of immunotherapy services. These changes apply to services
furnished beginning January 1, 2024. Additionally, this rule updates
the Quality Payment Program.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 08/07/23 88 FR 52262
NPRM Comment Period End............. 09/11/23
Final Action........................ 01/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Gift Tee, Director, Division of Physician Services,
Department of Health and Human Services, Centers for Medicare &
Medicaid Services, Center for Medicare, 7500 Security Boulevard, MS:
C1-09-07, Baltimore, MD 21244, Phone: 410 786-9316, Email:
[email protected].
RIN: 0938-AV07
342. CY 2024 Hospital Outpatient PPS Policy Changes and Payment Rates
and Ambulatory Surgical Center Payment System Policy Changes and
Payment Rates (CMS-1786) (Section 610 Review) [0938-AV09]
Legal Authority: 42 U.S.C. 1395hh; 42 U.S.C. 1302
Abstract: This annual final rule revises the Medicare hospital
outpatient prospective payment system to implement statutory
requirements and changes arising from our continuing experience with
this system. The rule describes changes to the amounts and factors used
to determine payment rates for services. In addition, the rule makes
changes to the ambulatory surgical center payment system list of
services and rates. This rule also updates and refines the requirements
for the Hospital Outpatient Quality Reporting (OQR)
[[Page 9586]]
Program and the ASC Quality Reporting (ASCQR) Program.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 07/31/23 88 FR 49552
NPRM Comment Period End............. 09/11/23
Final Action........................ 01/00/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Elise Barringer, Health Insurance Specialist,
Department of Health and Human Services, Centers for Medicare &
Medicaid Services, Center for Medicare, MS: C4-03-06, 7500 Security
Boulevard, Baltimore, MD 21244, Phone: 410 786-9222, Email:
[email protected].
RIN: 0938-AV09
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Centers for Medicare & Medicaid Services (CMS)
Completed Actions
343. FY 2024 Skilled Nursing Facility (SNF) PPS and Consolidated
Billing and Updates to the Value-Based Purchasing and Quality Reporting
Programs (CMS-1779) (Completion of a Section 610 Review) [0938-AV02]
Legal Authority: 42 U.S.C. 1395hh; 42 U.S.C. 1302
Abstract: This annual final rule updates the payment rates used
under the prospective payment system for SNFs for fiscal year 2024. The
rule also includes changes for the SNF Quality Reporting Program (QRP)
and for the Skilled Nursing Facility Value-Based Purchasing (VBP)
Program that will affect Medicare payment to SNFs.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 04/10/23 88 FR 21316
NPRM Comment Period End............. 06/05/23
Final Action........................ 08/07/23 88 FR 53200
Final Action Effective.............. 10/01/23
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Tammy Luo, Health Insurance Specialist, Department
of Health and Human Services, Centers for Medicare & Medicaid Services,
Center for Medicare, MS: C5-06-17, 7500 Security Boulevard, Baltimore,
MD 21244, Phone: 410 786-4325, Email: [email protected].
RIN: 0938-AV02
344. CY 2024 Home Health Prospective Payment System Rate Update and
Home Infusion Therapy Services Payment Update (CMS-1780) (Completion of
a Section 610 Review) [0938-AV03]
Legal Authority: 42 U.S.C. 1302; 42 U.S.C. 1395(fff); 42 U.S.C.
1395(m)
Abstract: This annual final rule updates the national, standardized
30-day period payment rate, national per-visit rates used to calculate
low utilization payment adjustments (LUPAs) and outlier payments under
the Medicare prospective payment system for home health agencies based
on the applicable home health payment update percentage. Additionally,
this rule updates payment rates for home infusion therapy services and
makes changes to the Medicare enrollment requirements for hospices.
These changes apply to services furnished on or after January 1, 2024.
This rule also makes changes to how the separate payment for negative
pressure wound therapy using a disposable device is made as required by
section 4136 of the Consolidated Appropriations Act of 2023 (CAA,
2023), and implements the permanent home intravenous immune globulin
services (IVIG) benefit as required by section 4134 of the CAA, 2023.
This rule addresses the scope of the Medicare Part B benefit for leg,
arm, back, and neck braces under section 1861(s)(9) of the Social
Security Act, and newer technology devices, as well as the
implementation of the Medicare Part B benefit for lymphedema
compression treatment items under section 1861(s)(2) of the Social
Security Act.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 07/10/23 88 FR 43654
NPRM Comment Period End............. 08/29/23
Final Action........................ 11/13/23 88 FR 77676
Final Action Effective.............. 01/01/24
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Brian Slater, Director, Division of Home Health and
Hospice, Department of Health and Human Services, Centers for Medicare
& Medicaid Services, Center for Medicare, MS: C4-07-07, 7500 Security
Boulevard, Baltimore, MD 21244, Phone: 410 786-5229, Email:
[email protected].
RIN: 0938-AV03
345. FY 2024 Inpatient Psychiatric Facilities Prospective Payment
System Rate and Quality Reporting Updates (CMS-1783) (Completion of a
Section 610 Review) [0938-AV06]
Legal Authority: 42 U.S.C. 1302; 42 U.S.C. 1395f; 42 U.S.C. 1395g;
42 U.S.C. 1395hh; . . .
Abstract: This annual final rule updates the prospective payment
system for inpatient psychiatric facilities (IPF) with discharges
beginning on October 1, 2023. The rule also includes updates to the IPF
Quality Reporting Program.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 04/10/23 88 FR 21238
NPRM Comment Period End............. 06/05/23
Final Action........................ 08/02/23 88 FR 51054
Final Action Effective.............. 10/01/23
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Nicolas Brock, Health Insurance Specialist,
Department of Health and Human Services, Centers for Medicare &
Medicaid Services, Center for Medicare, MS: C5-05-27, 7500 Security
Boulevard, Baltimore, MD 21244, Phone: 410 786-5148, Email:
[email protected].
RIN: 0938-AV06
346. Hospital Inpatient Prospective Payment Systems for Acute Care
Hospitals; the Long-Term Care Hospital Prospective Payment System; and
FY 2024 Rates (CMS-1785) (Completion of a Section 610 Review) [0938-
AV08]
Legal Authority: 42 U.S.C. 1395hh; 42 U.S.C. 1302
Abstract: This annual final rule revises the Medicare hospital
inpatient and long-term care hospital prospective payment systems for
operating and capital-related costs. This rule implements changes
arising from our continuing experience with these systems. In addition,
the rule establishes new requirements or revises existing requirements
for quality reporting by specific Medicare providers.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 05/01/23 88 FR 26658
NPRM Comment Period End............. 06/09/23
Final Action........................ 08/28/23 88 FR 58640
Final Action Effective.............. 10/01/23
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Donald Thompson, Director, Division of Acute Care,
[[Page 9587]]
Department of Health and Human Services, Centers for Medicare &
Medicaid Services, Center for Medicare, MS: C4-01-26, 7500 Security
Boulevard, Baltimore, MD 21244, Phone: 410 786-6504, Email:
[email protected].
RIN: 0938-AV08
347. FY 2024 Hospice Wage Index, Payment Rate Update, and Quality
Reporting Requirements (CMS-1787) (Completion of a Section 610 Review)
[0938-AV10]
Legal Authority: 42 U.S.C. 1302; 42 U.S.C. 1395hh
Abstract: This annual final rule updates the hospice payment rates
and the wage index for fiscal year 2024. The rule also finalizes
changes to the Hospice Quality Reporting program.
Timetable:
------------------------------------------------------------------------
Action Date FR Cite
------------------------------------------------------------------------
NPRM................................ 04/04/23 88 FR 20022
NPRM Comment Period End............. 05/30/23
Final Action........................ 08/02/23 88 FR 51164
Final Action Effective.............. 10/01/23
------------------------------------------------------------------------
Regulatory Flexibility Analysis Required: Yes.
Agency Contact: Brian Slater, Director, Division of Home Health and
Hospice, Department of Health and Human Services, Centers for Medicare
& Medicaid Services, Center for Medicare, MS: C4-07-07, 7500 Security
Boulevard, Baltimore, MD 21244, Phone: 410 786-5229, Email:
[email protected].
RIN: 0938-AV10
348. Hospital Outpatient Prospective Payment System: Remedy for 340B-
Acquired Drugs Purchased in Cost Years 2018-2022 (CMS-1793) (Section
610 Review) [0938-AV18]
Regulatory Plan: This entry is Seq. No. 77 in part II of this issue
of the Federal Register.
RIN: 0938-AV18
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Administration for Children and Families (ACF)
Proposed Rule Stage
349. Supporting the Head Start Workforce and Other Quality Improvements
[0970-AD01]
Regulatory Plan: This entry is Seq. No. 80 in part II of this issue
of the Federal Register.
RIN: 0970-AD01
350. Safe and Appropriate Foster Care Placement Requirements
for Titles IV-E and IV-B (Section 610 Review) [0970-AD03]
Regulatory Plan: This entry is Seq. No. 81 in part II of this issue
of the Federal Register.
RIN: 0970-AD03
[FR Doc. 2024-00453 Filed 2-8-24; 8:45 am]
BILLING CODE 4150-03-P